2
Risk for all vascular events across HDL- c quartiles, with or without lipid-lowering therapy HR 2 1 0,5 1 2 3 4 No lipid-lowering medication Lipid-lowering medication Van de Woestijne et al., JACC 2013

Risk for all vascular events across HDL-c quartiles, with or without lipid-lowering therapy

Embed Size (px)

DESCRIPTION

Risk for all vascular events across HDL-c quartiles, with or without lipid-lowering therapy. No lipid-lowering medication. 2. Lipid-lowering medication. 1. HR. 0,5. 1. 2. 3. 4. Van de Woestijne et al ., JACC 2013. - PowerPoint PPT Presentation

Citation preview

Page 1: Risk for all vascular events across HDL-c quartiles,  with or without lipid-lowering therapy

Risk for all vascular events across HDL-c quartiles, with or without lipid-lowering therapy

HR

2

1

0,5

1 2 3 4

No lipid-lowering medicationLipid-lowering medication

Van de Woestijne et al., JACC 2013

Page 2: Risk for all vascular events across HDL-c quartiles,  with or without lipid-lowering therapy

Risk for all vascular events across HDL-c quartiles, with/without intensive lipid-lowering therapy

1 2 3 4

HR

0,5

2

1

No intensive lipid-lowering therapyIntensive lipid-lowering therapy

Van de Woestijne et al., JACC 2013